Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03552276 · ClinicalTrials.gov registry record · Phase 2
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 281
- Enrollment target
NCT03552276 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 281 participants.
The verdict
NCT03552276, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 281 participants
- Enrollment target
Study Summary
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
Interventions
- DRUG SUNPG18_07 I (Tildrakizumab 200 mg)
- DRUG SUNPG18_07 II (Tildrakizumab 100 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03552276
The ClinicalTrials.gov registry entry for NCT03552276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SUNPG18_07 I (Tildrakizumab 200 mg) is the first listed.
NCT03552276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03552276 about?
NCT03552276 is a clinical study titled "Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.". A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
What is the current status of trial NCT03552276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2018-07-11. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT03552276?
The interventions under investigation include: SUNPG18_07 I (Tildrakizumab 200 mg) (DRUG), SUNPG18_07 II (Tildrakizumab 100 mg) (DRUG).
Who is sponsoring clinical trial NCT03552276?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.